ASCO Annual Meeting
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors
June 27, 2022
Article
Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
Adagrasib Demonstrates CNS Activity in KRAS G12C+ NSCLC
June 21, 2022
Article
The intracranial objective response rate was 32% among patients with KRAS G12C–mutant, non–small cell lung cancer who received adagrasib.
Roxadustat Increases Hemoglobin Counts in Patients With Chemotherapy-Induced Anemia
June 21, 2022
Article
Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat.
DRd Outperforms Rd in Newly Diagnosed Multiple Myeloma
June 19, 2022
Article
Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.
Frontline Panitumumab/mFOLFOX Elicits Longest Overall Survival To-Date in RAS Wild-Type Metastatic CRC
June 18, 2022
Article
Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.
Patritumab Deruxtecan Produces Early Responses in Advanced NSCLC Regardless of Variant Genomic Alterations
June 17, 2022
Article
Regardless of other identified driver genomic alterations, patients with heavily pretreated, advanced, non–small cell lung cancer achieved encouraging responses with patritumab deruxtecan.
Patients Receiving PD-1/PD-L1 Inhibitor Therapy More Frequently Experience Secondary Adrenal Insufficiency
June 17, 2022
Article
A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.
Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer
June 14, 2022
Article
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Close Monitoring With Adjuvant Abemaciclib Is Key To Treatment Continuation in High-Risk HR+/HER– Breast Cancer
June 13, 2022
Article
Patients with hormone receptor¬–positive, HER2-negative, node-positive high-risk early breast cancer who have certain characteristics may benefit from early dose adjustments with adjuvant abemaciclib.
5-Year Survival Data Showcases Long-Term Benefit With Nivolumab/Ipilimumab-Treated Metastatic NSCLC
June 12, 2022
Article
Frontline nivolumab and ipilimumab combination therapy was associated with increased 5-year survivorship in patients with metastatic non–small cell lung cancer—regardless of PD-L1 expression.